Funds › Armistice Capital, LLC
Armistice Capital, LLC
13F for Q2 2026, filed Aug 14, 2026. 323 positions worth $8.2B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$8.2B
+$2.5B (45.3%) vs Q1 2026
Positions
323
251 in Q1 2026
Top 10 share
12.1%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Armistice Capital, LLC in the latest 13F quarter?
Using 13F.ai, how has Armistice Capital, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Armistice Capital, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | MDGL Madrigal Pharmaceuticals, Inc. | 288,000 | $154.6M | 1.9% | +8.9% | 13F ↗ |
| 2 | SUPN Supernus Pharmaceuticals | 2.65M | $123.1M | 1.5% | +39.6% | 13F ↗ |
| 3 | CYTK Cytokinetics, Incorporated | 1.20M | $102.3M | 1.3% | +57.1% | 13F ↗ |
| 4 | INCY Incyte Corporation | 900,005 | $102.0M | 1.2% | +37.0% | 13F ↗ |
| 5 | NBIX Neurocrine Biosciences, Inc. | 535,838 | $90.3M | 1.1% | -26.0% | 13F ↗ |
| 6 | TVTX Travere Therapeutics, Inc. | 1.57M | $89.3M | 1.1% | -67.9% | 13F ↗ |
| 7 | AGIO Agios Pharmaceuticals, Inc. | 2.40M | $89.1M | 1.1% | -11.6% | 13F ↗ |
| 8 | PTCT PTC Therapeutics, Inc. | 1.07M | $87.4M | 1.1% | -48.4% | 13F ↗ |
| 9 | UNH UnitedHealth Group Incorporated | 183,000 | $76.1M | 0.9% | +23.6% | 13F ↗ |
| 10 | FRPT Freshpet, Inc. | 1.26M | $74.5M | 0.9% | +15.3% | 13F ↗ |
| 11 | DYN Dyne Therapeutics, Inc. | 3.09M | $68.6M | 0.8% | -2.8% | 13F ↗ |
| 12 | AMZN Amazon.com, Inc. | 284,562 | $67.8M | 0.8% | +8.6% | 13F ↗ |
| 13 | IMVT Immunovant, Inc. | 1.74M | $66.9M | 0.8% | -51.3% | 13F ↗ |
| 14 | RIGL Rigel Pharmaceuticals, Inc. | 1.67M | $65.4M | 0.8% | +30.6% | 13F ↗ |
| 15 | TMO Thermo Fisher Scientific Inc | 122,480 | $61.4M | 0.8% | +33.9% | 13F ↗ |
| 16 | IRWD Ironwood Pharmaceuticals, Inc. | 13.93M | $58.7M | 0.7% | -7.3% | 13F ↗ |
| 17 | HRMY Harmony Biosciences Holdings, Inc. | 1.56M | $56.9M | 0.7% | -3.7% | 13F ↗ |
| 18 | REGN Regeneron Pharmaceuticals, Inc. | 89,809 | $56.0M | 0.7% | +149% | 13F ↗ |
| 19 | NKTR Nektar Therapeutics | 724,000 | $50.5M | 0.6% | +25.3% | 13F ↗ |
| 20 | MLYS Mineralys Therapeutics, Inc. | 1.74M | $46.8M | 0.6% | +47.6% | 13F ↗ |
| 21 | SNY Sanofi | 1.06M | $45.4M | 0.6% | +255% | 13F ↗ |
| 22 | IMCR Immunocore Holdings plc · ADR | 1.43M | $45.3M | 0.6% | +20.2% | 13F ↗ |
| 23 | GOOGL Alphabet Inc. Class A | 126,494 | $45.2M | 0.6% | +6.7% | 13F ↗ |
| 24 | SLDB Solid Biosciences Inc. | 4.28M | $42.7M | 0.5% | +33.7% | 13F ↗ |
| 25 | MDB MongoDB, Inc. | 125,172 | $42.0M | 0.5% | +16.7% | 13F ↗ |
| 26 | KURA Kura Oncology, Inc. | 3.68M | $40.3M | 0.5% | -1.6% | 13F ↗ |
| 27 | XRAY DENTSPLY SIRONA Inc. | 3.67M | $39.0M | 0.5% | +22.4% | 13F ↗ |
| 28 | UBER Uber Technologies, Inc. | 497,908 | $35.9M | 0.4% | -4.0% | 13F ↗ |
| 29 | AXGN Axogen, Inc. | 775,000 | $35.8M | 0.4% | -17.2% | 13F ↗ |
| 30 | IRON Disc Medicine, Inc. | 460,000 | $33.6M | 0.4% | -14.2% | 13F ↗ |
| 31 | GTLB GitLab Inc. | 1.07M | $32.8M | 0.4% | +4.4% | 13F ↗ |
| 32 | FIVN Five9, Inc. | 1.54M | $32.7M | 0.4% | -3.5% | 13F ↗ |
| 33 | HUBS HubSpot, Inc. | 178,047 | $32.5M | 0.4% | +38.5% | 13F ↗ |
| 34 | ALGN Align Technology, Inc. | 180,286 | $30.4M | 0.4% | +14.1% | 13F ↗ |
| 35 | MSFT Microsoft Corporation | 80,581 | $30.1M | 0.4% | +64.9% | 13F ↗ |
| 36 | OFIX Orthofix Medical Inc. | 3.26M | $29.8M | 0.4% | +20.9% | 13F ↗ |
| 37 | HUM Humana Inc. | 72,527 | $28.8M | 0.4% | -48.7% | 13F ↗ |
| 38 | ANGO AngioDynamics, Inc. | 2.20M | $28.6M | 0.3% | +17.6% | 13F ↗ |
| 39 | WAT Waters Corporation | 75,004 | $28.1M | 0.3% | New | 13F ↗ |
| 40 | VSTM Verastem, Inc. | 7.02M | $26.8M | 0.3% | +53.0% | 13F ↗ |
| 41 | FDMT 4D Molecular Therapeutics, Inc. | 2.00M | $26.6M | 0.3% | Unchanged | 13F ↗ |
| 42 | NTLA Intellia Therapeutics, Inc. | 1.50M | $25.4M | 0.3% | +346% | 13F ↗ |
| 43 | WYNN Wynn Resorts, Limited | 261,065 | $25.3M | 0.3% | +50.4% | 13F ↗ |
| 44 | TMCI Treace Medical Concepts, Inc. | 6.36M | $25.3M | 0.3% | Unchanged | 13F ↗ |
| 45 | AUTL Autolus Therapeutics plc | 15.00M | $24.0M | 0.3% | -5.1% | 13F ↗ |
| 46 | ARVN Arvinas, Inc. | 2.80M | $23.2M | 0.3% | +41.4% | 13F ↗ |
| 47 | MGNX MacroGenics, Inc. | 5.01M | $23.1M | 0.3% | -16.7% | 13F ↗ |
| 48 | ANRO Alto Neuroscience, Inc. | 864,000 | $22.8M | 0.3% | -5.3% | 13F ↗ |
| 49 | TOST Toast, Inc. | 810,830 | $22.6M | 0.3% | +40.4% | 13F ↗ |
| 50 | PATH UiPath, Inc. | 2.00M | $21.7M | 0.3% | +55.7% | 13F ↗ |
Showing the top 50 of 323 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
169 new, 70 added to, 64 trimmed, 97 exited, 20 unchanged. By estimated dollars.
New positions (169)
| WAT Waters Corporation | 75,004 | New | $28.1M |
| ILMN Illumina, Inc. | 91,118 | New | $16.0M |
| PBH Prestige Consumer Healthcare Inc. | 336,000 | New | $15.9M |
| FWONK Liberty Media Corporation Series C | 165,106 | New | $15.7M |
| ITGR Integer Holdings Corporation | 167,746 | New | $15.7M |
| LYV Live Nation Entertainment, Inc. | 81,824 | New | $15.0M |
| NVO Novo Nordisk A/S · ADR | 312,000 | New | $15.0M |
| TWST Twist Bioscience Corporation | 142,000 | New | $14.6M |
| TTWO Take-Two Interactive Software, Inc. | 49,877 | New | $12.5M |
| MRVL Marvell Technology, Inc. | 39,978 | New | $11.9M |
Added to (70)
| CYTK Cytokinetics, Incorporated | 1.20M | +57.1% | $37.2M |
| SUPN Supernus Pharmaceuticals | 2.65M | +39.6% | $34.9M |
| REGN Regeneron Pharmaceuticals, Inc. | 89,809 | +149% | $33.5M |
| SNY Sanofi | 1.06M | +255% | $32.6M |
| INCY Incyte Corporation | 900,005 | +37.0% | $27.6M |
| NTLA Intellia Therapeutics, Inc. | 1.50M | +346% | $19.7M |
| ZETA Zeta Global Holdings Corp. | 965,273 | +8678% | $18.8M |
| TMO Thermo Fisher Scientific Inc | 122,480 | +33.9% | $15.5M |
| RIGL Rigel Pharmaceuticals, Inc. | 1.67M | +30.6% | $15.3M |
| MLYS Mineralys Therapeutics, Inc. | 1.74M | +47.6% | $15.1M |
Trimmed (64)
| TVTX Travere Therapeutics, Inc. | 1.57M | -67.9% | -$188.9M |
| PTCT PTC Therapeutics, Inc. | 1.07M | -48.4% | -$81.8M |
| IMVT Immunovant, Inc. | 1.74M | -51.3% | -$70.5M |
| DDOG Datadog, Inc. | 37,679 | -81.9% | -$44.5M |
| NBIX Neurocrine Biosciences, Inc. | 535,838 | -26.0% | -$31.7M |
| HUM Humana Inc. | 72,527 | -48.7% | -$27.3M |
| PENN PENN Entertainment, Inc. | 672,000 | -57.4% | -$19.4M |
| MU Micron Technology, Inc. | 11,567 | -50.3% | -$13.5M |
| INTC Intel Corporation | 129,011 | -42.4% | -$13.3M |
| S SentinelOne, Inc. | 1.21M | -36.5% | -$11.7M |
Exited (97)
| Avanos Med Inc | 2.00M | Exited | -$28.0M |
| MDLN Medline Inc. | 564,857 | Exited | -$25.1M |
| Kalvista Pharmaceuticals Inc | 1.24M | Exited | -$24.9M |
| ENR Energizer Holdings, Inc. | 1.20M | Exited | -$19.7M |
| META Meta Platforms, Inc. | 32,594 | Exited | -$18.6M |
| Esperion Therapeutics Inc Ne | 3.93M | Exited | -$10.8M |
| IQV IQVIA Holdings, Inc. | 60,884 | Exited | -$10.4M |
| SGMOQ Sangamo Therapeutics Inc · Com D | 40.40M | Exited | -$10.0M |
| GEHC GE HealthCare Technologies Inc. | 118,289 | Exited | -$8.4M |
| TENX Tenax Therapeutics, Inc. | 478,827 | Exited | -$7.7M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer